Ligand Pharmaceuticals (LGND) saw its stock price plummet 5.25% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results. The biopharmaceutical company reported significant losses, disappointing investors and triggering a sell-off.
According to the earnings report, Ligand posted a basic earnings per share (EPS) of -$2.21 for Q1 2025. The company's operating income came in at -$36.216 million, while its pretax profit stood at a concerning -$50.18 million. These figures paint a picture of substantial financial challenges faced by the company in the first quarter.
Despite the negative results, Ligand Pharmaceuticals has reaffirmed its financial guidance for 2025, suggesting that the company remains optimistic about its long-term prospects. However, the market's immediate reaction indicates that investors are more focused on the current performance rather than future projections. As trading continues, it remains to be seen whether Ligand can regain investor confidence and reverse this downward trend.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。